Anzeige
Erschienen in:
11.02.2019 | ORIGINAL ARTICLE
Characteristics and Cardiovascular Disease Event Rates among African Americans and Whites Who Meet the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) Trial Inclusion Criteria
Erschienen in: Cardiovascular Drugs and Therapy | Ausgabe 2/2019
Einloggen, um Zugang zu erhaltenAbstract
Purpose
Determine the risk for cardiovascular disease (CVD) events among adults with clinically evident CVD who meet the inclusion criteria for the FOURIER clinical trial on PCSK9 inhibition in a real-world database.
Methods
We analyzed data from 2072 African American and 2972 white REasons for Geographic And Racial Differences in Stroke (REGARDS) study participants 45–85 years of age with clinically evident CVD. Study participants meeting the FOURIER inclusion criteria (one major or two minor cardiovascular risk factors, fasting LDL cholesterol ≥ 70 mg/dL or non-HDL cholesterol ≥ 100 mg/dL, triglycerides ≤ 400 mg/dL, and taking statin) were followed for CVD events (myocardial infarction, stroke, coronary revascularization, and CVD death) from baseline in 2003–2007 through 2014.
Results
Overall, 771 (37.2%) African Americans and 1200 (40.4%) whites met the FOURIER inclusion criteria. The CVD event rate per 1000 person years was 60.6 (95% CI 53.6–67.6) among African Americans and 63.5 (95% CI 57.7–69.3) among whites. The risk for CVD events among adults meeting the FOURIER inclusion criteria was higher for those with a history of multiple cardiovascular events (hazard ratios among African Americans and whites 1.34 [95% CI 1.05–1.71] and 1.34 [1.10–1.63], respectively), a prior coronary revascularization (1.44 [1.13–1.84] and 1.23 [1.00–1.52], respectively), diabetes (1.38 [1.08–1.76] and 1.41 [1.15–1.72], respectively), reduced glomerular filtration rate (1.63 [1.26–2.11] and 1.29 [1.03–1.62], respectively), and albuminuria (1.77 [1.37–2.27] and 1.33 [1.07–1.65], respectively).
Conclusions
The CVD event rate is high among African Americans and whites meeting the FOURIER inclusion criteria. Characteristics associated with a higher CVD risk may inform the decision to initiate PCSK9 inhibition.